Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05FCR
|
|||
| Drug Name |
GT0918
|
|||
| Synonyms |
KCBJGVDOSBKVKP-UHFFFAOYSA-N; UNII-QX6O64GP40; QX6O64GP40; 1398046-21-3; GT-0918; SCHEMBL12494226; 4-(4,4-Dimethyl-3-(6-(3-(2-oxazolyl)propyl)-3-pyridinyl)-5-oxo-2-thioxo-1-imidazolidinyl)-3-fluoro-2-(trifluoromethyl)-benzonitrile
Click to Show/Hide
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [1] | |
| Prostate cancer [ICD-11: 2C82.0] | Phase 1/2 | [2] | ||
| Company |
Suzhou Kintor Pharmaceuticals Suzhou, China
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H19F4N5O2S
|
|||
| Canonical SMILES |
CC1(C(=O)N(C(=S)N1C2=CN=C(C=C2)CCCC3=NC=CO3)C4=C(C(=C(C=C4)C#N)C(F)(F)F)F)C
|
|||
| InChI |
1S/C24H19F4N5O2S/c1-23(2)21(34)32(17-9-6-14(12-29)19(20(17)25)24(26,27)28)22(36)33(23)16-8-7-15(31-13-16)4-3-5-18-30-10-11-35-18/h6-11,13H,3-5H2,1-2H3
|
|||
| InChIKey |
KCBJGVDOSBKVKP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1398046-21-3
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04728802) Proxalutamide Treatment for Hospitalized COVID-19 Patients. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.